Intervacc AB Share Price

IVACC

SE0009607252

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 17:00:00 31/07/2026 BST			5-day change	1st Jan Change
1.270 ^SEK	-1.24%		+3.93%	+37.45%

07-30	Intervacc Submits Type Ii Variation Application to Ema Seeking 12-Month Duration of Immunity for Strangvac	CI
07-30	Intervacc Seeks EU Regulatory Approval to Extend Horse Vaccine's Immunity Duration	MT

Analysts' recommendations: Intervacc AB

20/05/24	Penser reiterates motivated value for Intervacc - report met expectations	FW
21/02/24	Penser lowers Intervacc's motivated value	FW
17/11/23	Penser makes minor estimate adjustments in Intervacc	FW
04/05/23	Penser lowers its motivated value for Intervacc to SEK 26-28 (48-54)	FW
20/02/23	Penser halves the motivated value for Intervacc - which falls on the stock exchange	FW

More recommendations

Managers and Directors: Intervacc AB

Manager	Title	Age	Since
Carl-Johan Dalsgaard CEO	Chief Executive Officer	70	04/02/2026
Jan Persson DFI	Director of Finance/CFO	-	05/02/2020
Andrew Waller CTO	Chief Tech/Sci/R&D Officer	-	10/06/2020

Director	Title	Age	Since
Björn Ingemar Odlander BRD	Director/Board Member	68	31/12/2024
Carl Erik Mathias Uhlén BRD	Director/Board Member	72	31/12/2023
Erling Lennart Johansson BRD	Director/Board Member	71	31/12/2022

More insiders

Intervacc AB is a Sweden-based biotechnology company. It develops vaccines based on recombinant proteins for animal health care. The Companyâ€™s candidate vaccine against strangles Strangvac consists of soluble recombinant proteins and devoids any living infectious agent. The Company operates through two subsidiaries: Nord Vacc Lakemedel AB and Mybac-Vettech AB. Nord Vacc Lakemedel AB markets and distributes veterinary vaccines, pharmaceuticals and vitamins on European market. It offers assortment of fur animal vaccines, the Febrivac range, as well as swine vaccines for Swedish and Danish markets. Mybac-Vettech AB is a technology platform that focuses on diagnostics in the Swedish animal health market and offers bacteriological and mycological analyses.

Employees

Sector

Biotechnology & Medical Research

Calendar

08-20 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
31/07/26	SEK 1.270	-1.24%	218,129
30/07/26	SEK 1.286	+0.78%	325,555
29/07/26	SEK 1.276	+2.57%	359,093
28/07/26	SEK 1.244	-2.05%	178,095
27/07/26	SEK 1.270	0.00%	171,971

Delayed Quote Nasdaq Stockholm

More quotes

Income Statement and Estimates

More financial data

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Cap	433M 45.38M 39.45M 36.72M 33.71M 63.66M 4.33B 64.65M 170M 2.16B 170M 167M 7.23B	P/E 2026 *	-5.85x	P/E 2027 *	-5.85x
Enterprise Value	340M 35.63M 30.97M 28.83M 26.47M 49.99M 3.4B 50.76M 133M 1.69B 134M 131M 5.68B	EV / Sales 2026 *	19.2x	EV / Sales 2027 *	12.3x
Free-Float	80.66%	Yield 2026 *	-	Yield 2027 *	-

07-30	Intervacc Submits Type Ii Variation Application to Ema Seeking 12-Month Duration of Immunity for Strangvac	CI
07-30	Intervacc Seeks EU Regulatory Approval to Extend Horse Vaccine's Immunity Duration	MT
07-29	Intervacc Gets Special Approval to Send Equine Vaccine to New Zealand	MT
07-29	Intervacc AB Publ Makes First Export Of Strangvac To New Zealand Under Special Circumstances Permit	CI
05-22	Intervacc AB Completes Successful Evaluation of Us Strain of Strangles Pathogen Ahead of Clinical Trials	CI
05-15	Sweden's Intervacc Elects New Chair	MT
05-15	Appoints Emil Billbäck as chairman	RE
05-13	Intervacc elects Emil Billbäck as chairperson of board	RE
05-13	Intervacc AB Announces Board Changes	CI
05-13	Intervacc Q1 net sales down at SEK 3.4 million	RE
05-13	Intervacc AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-12	Intervacc AB Announces Appointment of Lars Stubberud as Chief Technology Officer, Effective July 15, 2026	CI
04-16	Intervacc: Strangvac vaccine approved in Iceland	RE

07-30	Intervacc submits Type II variation to EMA seeking 12-month duration of immunity for Strangvac	AQ
07-29	Intervacc: New Zealand order validates Strangvac’s position	AQ
07-29	Intervacc makes first export of Strangvac to New Zealand under Special Circumstances Permit	AQ
06-04	Redeye initiates coverage of Intervacc	AQ
05-22	Intervacc: Positive results	AQ

1 day	-1.24%
1 week	+3.93%
Current month	-2.61%
1 month	-2.61%
3 months	+11.21%
6 months	+46.14%
Current year	+37.45%

1 week	1.21	1.35
1 month	1	1.36
Current year	0.57	1.46
1 year	0.57	1.46
3 years	0.57	10.46
5 years	0.57	84
10 years	0.57	95.5

Intervacc AB Share Price

Stocks

IVACC

SE0009607252

Biotechnology & Medical Research

Valuation: Intervacc AB

Chart: Intervacc AB

Latest news : Intervacc AB

Analysts' recommendations: Intervacc AB

Press Releases: Intervacc AB

Quotes and Performance

Course Extremes

Managers and Directors: Intervacc AB

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Quarterly revenue - Rate of surprise

Date	Insider	Type	Main position	Quantity	% Market Cap.
23/02/25	Jan Persson	Free	Chief Financial Officer	929,208	1.2269%
17/02/25	Jonas Sohlman	Buy	Chief Executive Officer	135,000	0.1783%
17/02/25	Jan-Ingmar Flock	Sell	Chief Executive Officer	278,820	0.3681%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
INTERVACC AB	-1.24%	+3.93%	+8.73%	-74.11%	45.9M
WUXI APPTEC CO., LTD.	+2.35%	+0.77%	+29.92%	+85.38%	55.23B
ARGENX SE	-0.21%	-6.52%	+42.39%	+64.10%	53.75B
BIONTECH SE	-2.44%	+1.40%	-15.74%	-16.80%	23.48B
INSMED INCORPORATED	-2.85%	-7.78%	-8.09%	+346.36%	22B
WUXI BIOLOGICS (CAYMAN) INC.	+2.49%	-1.27%	+15.99%	-10.53%	19.78B
GENMAB A/S	+0.79%	-2.39%	+26.99%	-31.34%	17.44B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.58%	-7.23%	+24.50%	+519.07%	14.66B
EXELIXIS, INC.	-5.25%	-4.23%	+46.41%	+169.05%	14.07B
PHARMAESSENTIA CORPORATION	+3.41%	-7.83%	+161.76%	+284.91%	13.02B
Average	-0.24%	+0.12%	+33.29%	+133.61%	23.35B
Weighted average by Cap.	+0.17%	+0.10%	+31.22%	+121.31%

	2026 *	2027 *
Net sales	17.7M 1.86M 1.61M 1.5M 1.38M 2.6M 177M 2.64M 6.95M 88.2M 6.97M 6.82M 296M	30.05M 3.15M 2.74M 2.55M 2.34M 4.42M 301M 4.49M 11.79M 150M 11.83M 11.57M 502M
Net income	-80.8M -8.47M -7.36M -6.85M -6.29M -11.88M -809M -12.07M -31.71M -403M -31.82M -31.12M -1.35B	-83.65M -8.77M -7.62M -7.1M -6.52M -12.3M -837M -12.49M -32.83M -417M -32.94M -32.22M -1.4B
Net Debt	-93M -9.75M -8.48M -7.89M -7.24M -13.68M -931M -13.89M -36.5M -463M -36.62M -35.82M -1.55B	-63M -6.61M -5.74M -5.34M -4.91M -9.27M -631M -9.41M -24.73M -314M -24.81M -24.26M -1.05B